📢 Gate Square #Creator Campaign Phase 2# is officially live!
Join the ZKWASM event series, share your insights, and win a share of 4,000 $ZKWASM!
As a pioneer in zk-based public chains, ZKWASM is now being prominently promoted on the Gate platform!
Three major campaigns are launching simultaneously: Launchpool subscription, CandyDrop airdrop, and Alpha exclusive trading — don’t miss out!
🎨 Campaign 1: Post on Gate Square and win content rewards
📅 Time: July 25, 22:00 – July 29, 22:00 (UTC+8)
📌 How to participate:
Post original content (at least 100 words) on Gate Square related to
This year's investment journey has been filled with challenges and opportunities. I am pleased to announce that my personal portfolio has reached a new high for the year, with profits increasing by 800,000 yuan. Based on a foundation of 3 million yuan, the return rate has reached 26.7%, successfully outperforming the performance of major indices.
In this delightful report card, the performance of the pharmaceutical sector is particularly outstanding. Among them, a pharmaceutical stock that I am paying special attention to has not only reached a new high this year, but has also become a pillar supporting the entire investment portfolio. The excellent performance of this stock makes me even more confident about the development prospects of the pharmaceutical industry.
It is worth mentioning that the H-shares of this pharmaceutical stock have performed exceptionally well. From the beginning of the year to now, it has not only reversed a 22% lag behind A-shares but has also achieved a 12% lead. This counter-trend performance is indeed exciting.
Looking at the entire pharmaceutical sector, the H-shares of this stock have increased by 68% so far this year. Although this is still slightly lower than the 75% increase of the Hang Seng Pharmaceutical ETF, the gap has narrowed from 20% earlier to just 7% now. I am very optimistic about its potential to catch up and surpass the ETF performance in the near future.
In addition, another stock that I am paying attention to is also showing positive technical signals. Its 50-day moving average has bottomed out, indicating that a wave of upward trend may be coming soon. I have high expectations for it to reach a historical high this month.
Overall, this investment report is encouraging. It not only reflects the success of individual investment strategies but also confirms the investment value of the pharmaceutical industry in the current market environment. In the future, I will continue to closely monitor market trends and strive to find more quality investment opportunities to achieve better investment returns.